177 related articles for article (PubMed ID: 21738026)
1. The dubious effect of milnacipran for the treatment of burning mouth syndrome.
Sugimoto K
Clin Neuropharmacol; 2011; 34(4):170-3. PubMed ID: 21738026
[TBL] [Abstract][Full Text] [Related]
2. Milnacipran dose-effect study in patients with burning mouth syndrome.
Kato Y; Sato T; Katagiri A; Umezaki Y; Takenoshita M; Yoshikawa T; Sato Y; Toyofuku A
Clin Neuropharmacol; 2011; 34(4):166-9. PubMed ID: 21738023
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region.
Ito M; Kimura H; Yoshida K; Kimura Y; Ozaki N; Kurita K
Clin Neuropharmacol; 2010; 33(2):79-83. PubMed ID: 20375656
[TBL] [Abstract][Full Text] [Related]
4. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.
Clauw DJ; Mease P; Palmer RH; Gendreau RM; Wang Y
Clin Ther; 2008 Nov; 30(11):1988-2004. PubMed ID: 19108787
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of low-dose milnacipran for a patient suffering from pain disorder with delusional disorder (somatic type) in the orofacial region.
Ukai K; Kimura H; Arao M; Aleksic B; Yamauchi A; Ishihara R; Iritani S; Kurita K; Ozaki N
Psychogeriatrics; 2013 Jun; 13(2):99-102. PubMed ID: 23909967
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.
Arnold LM; Gendreau RM; Palmer RH; Gendreau JF; Wang Y
Arthritis Rheum; 2010 Sep; 62(9):2745-56. PubMed ID: 20496365
[TBL] [Abstract][Full Text] [Related]
7. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia.
Branco JC; Zachrisson O; Perrot S; Mainguy Y;
J Rheumatol; 2010 Apr; 37(4):851-9. PubMed ID: 20156949
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.
Mease PJ; Clauw DJ; Gendreau RM; Rao SG; Kranzler J; Chen W; Palmer RH
J Rheumatol; 2009 Feb; 36(2):398-409. PubMed ID: 19132781
[TBL] [Abstract][Full Text] [Related]
9. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome.
Häuser W; Urrútia G; Tort S; Uçeyler N; Walitt B
Cochrane Database Syst Rev; 2013 Jan; (1):CD010292. PubMed ID: 23440848
[TBL] [Abstract][Full Text] [Related]
10. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
Welsch P; Üçeyler N; Klose P; Walitt B; Häuser W
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD010292. PubMed ID: 29489029
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study.
Maina G; Vitalucci A; Gandolfo S; Bogetto F
J Clin Psychiatry; 2002 Jan; 63(1):38-43. PubMed ID: 11838624
[TBL] [Abstract][Full Text] [Related]
12. Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial.
Natelson BH; Vu D; Mao X; Weiduschat N; Togo F; Lange G; Blate M; Kang G; Coplan JD; Shungu DC
J Pain; 2015 Nov; 16(11):1211-9. PubMed ID: 26335989
[TBL] [Abstract][Full Text] [Related]
13. Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial.
Lee YC; Massarotti E; Edwards RR; Lu B; Liu C; Lo Y; Wohlfahrt A; Kim ND; Clauw DJ; Solomon DH
J Rheumatol; 2016 Jan; 43(1):38-45. PubMed ID: 26628607
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of milnacipran for the treatment of chronic pain: a case series.
Kamata M; Takahashi H; Naito S; Higuchi H
Clin Neuropharmacol; 2004; 27(5):208-10. PubMed ID: 15602099
[TBL] [Abstract][Full Text] [Related]
15. Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial.
Staud R; Lucas YE; Price DD; Robinson ME
J Pain; 2015 Aug; 16(8):750-9. PubMed ID: 25998206
[TBL] [Abstract][Full Text] [Related]
16. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of fluoxetine in BMS-A cross-over study.
Zoric B; Jankovic L; Kuzmanovic Pficer J; Zidverc-Trajkovic J; Mijajlovic M; Stanimirovic D
Gerodontology; 2018 Jun; 35(2):123-128. PubMed ID: 29575009
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury.
Kanetani K; Kimura M; Endo S
J Nippon Med Sch; 2003 Aug; 70(4):313-20. PubMed ID: 12928711
[TBL] [Abstract][Full Text] [Related]
19. Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression.
Okumura K; Furukawa TA
Clin Drug Investig; 2006; 26(3):135-42. PubMed ID: 17163244
[TBL] [Abstract][Full Text] [Related]
20. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial.
Matthey A; Cedraschi C; Piguet V; Besson M; Chabert J; Daali Y; Courvoisier D; Montagne A; Dayer P; Desmeules JA
Pain Physician; 2013; 16(5):E553-62. PubMed ID: 24077206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
